Finally, we showed that high expression of PDK1 was associated with progressive disease in EGFR mutant NSCLC patients, as shown by immunohistochemistry (IHC), suggesting they could be responsive to osimertinib and PDK1 inhibitor combination therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.